Informations sur le produit
- 3-[[3-Bromo-2-[2-(Trifluoromethylsulfonylamino)Phenyl]-1-Benzofuran-5-Yl]Methyl]-5-Cyclopropyl-2-Ethylimidazole-4-Carboxamide
- 1-[[3-Bromo-2-[2-[[(trifluoromethyl)sulfonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
- 1H-Imidazole-5-carboxamide, 1-[[3-bromo-2-[2-[[(trifluoromethyl)sulfonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-
- GR 138950
Saprisartan is a selective angiotensin II receptor antagonist, which blocks the binding of angiotensin II to the AT1 receptor. It has been shown to inhibit the enzyme angiotensin converting enzyme (ACE) in human serum and plasma. Saprisartan has been shown to be safe for use during pregnancy, as it does not cross the placenta and therefore does not affect fetal blood pressure. This drug also reduces systolic blood pressure and increases diastolic blood pressure in patients with congestive heart failure. Saprisartan is an antihypertensive drug that can be used to treat high blood pressure, hypertension, or edema.